データを補完しています。通常は 1 分以内に完了します
基本情報
- CAS
959-24-0- 標準SMILES
CC(C)NCC(O)c1ccc(NS(C)(=O)=O)cc1.Cl- InChIKey
VIDRYROWYFWGSY-UHFFFAOYSA-N- 分子式
- C12H21ClN2O3S
- 平均分子量
- 308.83 g/mol
概要
Sotalol hydrochloride is a hydrochloride salt that is the monohydrochloride of sotalol. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias. It has a role as a beta-adrenergic antagonist and an anti-arrhythmia drug. It contains a sotalol(1+).
名称と識別子
- 優先名称
- Sotalol Hydrochloride
- IUPAC
- N-[4-[1-hydroxy-2-(propan-2-ylamino)ethyl]phenyl]methanesulfonamide;hydrochloride
名称と別名
Sotalol hydrochloride959-24-0Sotalol HCLBetapaceBetapace AFSotacorSotalexSorineSotylizeBerlexMJ 1999Darob
名称をさらに表示
Sotalol MonohydrochlorideHEC37C70XXIsopropylaminohydroxyethylmethanesulfonanilide hydrochloride4'-(1-Hydroxy-2-(isopropylamino)ethyl)methanesulfonanilide monohydrochlorideNSC-337251NSC-760358DTXSID8021278N-Isopropyl-beta-(4-methanesulfonamidophenyl)ethanolamine hydrochloride
データベース識別子
- CAS
959-24-0- PubChem CID
- 66245
- ChEMBL
CHEMBL1700- ChEBI
CHEBI:9207- UNII
- HEC37C70XX
- EC Number
- 213-496-0
物性
構造計算による物性補完中
- 極性表面積
- 86.8 Ų
- 水素結合供与体数
- 4
- 水素結合受容体数
- 5
- 回転可能結合数
- 6
- 重原子数
- 19
- 形式電荷
- 0
- 複雑度
- 330
実験および物理化学的性質
Solubility>46.3 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Adrenergic Beta-Antagonists; Antiarrhythmics
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Collision Cross Section166.3 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]
安全と法規制
GHS分類
GHS Classification
This chemical does not meet GHS hazard criteria for 1.4% (1 of 73) of reports.
Warning
H315 (94.5%): Causes skin irritation [Warning Skin corrosion/irritation]
P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 73 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
危険有害性情報
Other Safety InformationIMAP assessments - Methanesulfonamide, N-[4-[1-hydroxy-2-[(1-methylethyl)amino]ethyl]phenyl]-, monohydrochloride: Environment tier I assessment
Hazard Classes and CategoriesSkin Irrit. 2 (94.5%)
毒性情報
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Sotalol hydrochloride
Ambiguous-DILI-concern
3
Adverse reactions
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
化学と産業
薬理情報
FDA Pharmacological Classification
SOTALOL HYDROCHLORIDE
Cardiac Rhythm Alteration [PE]; Antiarrhythmic [EPC]; Adrenergic beta-Antagonists [MoA]
SOTALOL HYDROCHLORIDE TABLES AF
Adrenergic beta-Antagonists [MoA]; Antiarrhythmic [EPC]; Cardiac Rhythm Alteration [PE]
SOTALOL HYDROCHLORIDE TABLETS AF
Antiarrhythmic [EPC]; Adrenergic beta-Antagonists [MoA]; Cardiac Rhythm Alteration [PE]
MeSH Pharmacological Classification
Drugs that bind to but do not activate beta-adrenergic receptors thereby blocking the actions of beta-adrenergic agonists. Adrenergic beta-antagonists are used for treatment of hypertension, cardiac arrhythmias, angina pectoris, glaucoma, migraine headaches, and anxiety.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
関連反応
4 件
化合物ノート
読み込み中…